Enzo Biochem Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Enzo Biochem.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Healthcare earnings growth	17.2%
Revenue growth rate	n/a
Future return on equity	n/a
Analyst coverage	None
Last updated	n/a

Recent future growth updates

Recent updates

If You Had Bought Enzo Biochem's (NYSE:ENZ) Shares Three Years Ago You Would Be Down 66%

Jan 08

Enzo Biochem nabs expanded EUA nod for testing of COVID samples

Jan 04

Enzo Biochem: Betting On The Activists Now

Dec 16

Here's What We Think About Enzo Biochem's (NYSE:ENZ) CEO Pay

Dec 13

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Enzo Biochem has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

NYSE:ENZ - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
4/30/2024	33	-18	-43	-42	N/A
1/31/2024	33	-23	-46	-44	N/A
10/31/2023	32	-25	-44	-42	N/A
7/31/2023	31	-25	-40	-37	N/A
4/30/2023	-32	-27	-32	-29	N/A
1/31/2023	-13	-24	-28	-25	N/A
10/31/2022	13	-23	-22	-19	N/A
7/31/2022	33	-20	-20	-17	N/A
4/30/2022	112	-7	-12	-7	N/A
1/31/2022	118	0	-10	-4	N/A
10/31/2021	116	5	-9	-4	N/A
7/31/2021	118	8	-4	0	N/A
4/30/2021	112	1	-9	-5	N/A
1/31/2021	97	-11	-14	-11	N/A
10/31/2020	84	-21	-19	-16	N/A
7/31/2020	76	-29	-19	-17	N/A
4/30/2020	77	-31	-17	-15	N/A
1/31/2020	80	2	10	12	N/A
10/31/2019	80	1	1	9	N/A
7/31/2019	81	2	-3	5	N/A
4/30/2019	83	2	-2	6	N/A
1/31/2019	89	-23	-26	-18	N/A
10/31/2018	95	-16	-13	-12	N/A
7/31/2018	101	-10	-5	-3	N/A
4/30/2018	106	-4	-1	1	N/A
1/31/2018	108	-2	N/A	3	N/A
10/31/2017	108	-2	N/A	3	N/A
7/31/2017	105	-3	N/A	0	N/A
4/30/2017	106	34	N/A	34	N/A
1/31/2017	106	31	N/A	30	N/A
10/31/2016	104	39	N/A	40	N/A
7/31/2016	103	45	N/A	53	N/A
4/30/2016	102	18	N/A	21	N/A
1/31/2016	99	17	N/A	23	N/A
10/31/2015	98	6	N/A	12	N/A
7/31/2015	98	-2	N/A	-4	N/A
4/30/2015	97	-14	N/A	-7	N/A
1/31/2015	97	-11	N/A	-3	N/A
10/31/2014	97	-11	N/A	-1	N/A
7/31/2014	96	-10	N/A	-2	N/A
4/30/2014	94	-10	N/A	-4	N/A
1/31/2014	93	-15	N/A	-10	N/A
10/31/2013	92	-17	N/A	-12	N/A
7/31/2013	94	-18	N/A	-10	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if ENZ's forecast earnings growth is above the savings rate (2.4%).

Earnings vs Market: Insufficient data to determine if ENZ's earnings are forecast to grow faster than the US market

High Growth Earnings: Insufficient data to determine if ENZ's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if ENZ's revenue is forecast to grow faster than the US market.

High Growth Revenue: Insufficient data to determine if ENZ's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if ENZ's Return on Equity is forecast to be high in 3 years time

Enzo Biochem Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Enzo Biochem, Inc. Provides Earnings Guidance for the Years 2023, 2024, 2025, 2026 and 2027

Recent updates

Third quarter 2024 earnings released: US$0.042 loss per share (vs US$0.31 loss in 3Q 2023)

Second quarter 2024 earnings released: US$0.017 loss per share (vs US$0.059 loss in 2Q 2023)

Enzo Biochem, Inc. Appoints Kara Cannon to Serve as the Chief Executive Officer

Enzo Biochem, Inc., Annual General Meeting, Jan 31, 2024

Enzo Biochem, Inc. announced delayed annual 10-K filing

Enzo Biochem, Inc. Appoints Steven J. Pully to its Board of Directors

Enzo Biochem: Cleaned Up And Cash-Rich But Unloved

High number of new and inexperienced directors

Enzo Biochem, Inc. Announces CEO Changes

Is Enzo Biochem (NYSE:ENZ) Using Debt Sensibly?

Enzo Biochem, Inc. Provides Earnings Guidance for the Years 2023, 2024, 2025, 2026 and 2027

Second quarter 2023 earnings released: US$0.23 loss per share (vs US$0.055 loss in 2Q 2022)

Is Enzo Biochem (NYSE:ENZ) A Risky Investment?

First quarter 2023 earnings released: US$0.22 loss per share (vs US$0.048 loss in 1Q 2022)

Enzo Biochem Non-GAAP EPS of -$0.18, revenue of $18.28M

Enzo Biochem, Inc. to Report Q1, 2023 Results on Dec 12, 2022

CEO & Director recently bought US$197k worth of stock

Insider recently bought US$5.0m worth of stock

High number of new and inexperienced directors

Enzo Biochem, Inc., Annual General Meeting, Jan 31, 2023

Enzo Biochem, Inc. Announces Resignation of David Bench as Senior Vice President, Treasurer and Corporate Secretary, Effective November 14, 2022

Enzo Biochem appoints Patricia Eckert as interim CFO

Full year 2022 earnings released

Enzo Biochem Non-GAAP EPS of -$0.17, revenue of $20.28M

Enzo Biochem, Inc. to Report Q4, 2022 Results on Oct 14, 2022

Does Enzo Biochem (NYSE:ENZ) Have A Healthy Balance Sheet?

Enzo Biochem, Inc. Launches Ampiview Gene Expression Platform with First Products Targeting Detection of HPV and Sars-Cov-2

Enzo Biochem, Inc. to Launch Monkeypox Testing Services This Week

Enzo Biochem, Inc. Announces Executive Changes

Independent Director recently bought US$264k worth of stock

Enzo Biochem: Activist Pressure Could Finally Lead To A Company Sale

Independent Director recently bought US$276k worth of stock

Third quarter 2022 earnings released: US$0.10 loss per share (vs US$0.041 profit in 3Q 2021)

Enzo Biochem, Inc. to Report Q3, 2022 Results on Jun 09, 2022

Is Enzo Biochem (NYSE:ENZ) Using Debt In A Risky Way?

High number of new and inexperienced directors

Enzo Biochem Announces New York State Department of Health Approval of HPV Molecular Diagnostic Test

Enzo Biochem, Inc., Annual General Meeting, Apr 08, 2022

Enzo Biochem, Inc., Annual General Meeting, Apr 08, 2022

Enzo Biochem, Inc. Appoints David Bench and Kara Cannon to New Executive Management Positions

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Enzo Biochem, Inc. Announces Resignation of Barry Weiner as President, Effective April 19, 2022

High number of new and inexperienced directors

Less than half of directors are independent

Insider recently bought US$2.5m worth of stock

Is Enzo Biochem (NYSE:ENZ) A Risky Investment?

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Insider recently bought US$1.5m worth of stock

Investor sentiment deteriorated over the past week

Full year 2021 earnings released: EPS US$0.16 (vs US$0.60 loss in FY 2020)

Insider recently bought US$2.5m worth of stock

Health Check: How Prudently Does Enzo Biochem (NYSE:ENZ) Use Debt?

Enzo Biochem, Inc.(NYSE:ENZ) dropped from Russell 3000E Value Index

Third quarter 2021 earnings released: EPS US$0.041 (vs US$0.21 loss in 3Q 2020)

Enzo Biochem, Inc. Rejects Elazar Rabbani’s Previous Tender of Resignation as a Director

Second quarter 2021 earnings released: EPS US$0.048 (vs US$0.16 loss in 2Q 2020)

Enzo Biochem, Inc. Announces Resignation of Elazar Rabbani as CEO

Enzo Announces Its Genflex Molecular Test Detects Current Covid-19 Variants

Enzo Biochem, Inc. to Report Q2, 2021 Results on Mar 15, 2021

Does Enzo Biochem (NYSE:ENZ) Have A Healthy Balance Sheet?

New 90-day high: US$3.25

Enzo Biochem, Inc. Announces Issuance of U.S. Patent for Polyclonal Antibodies Against Osteoporosis Drug Target Sclerostin

Is Enzo Biochem, Inc. (NYSE:ENZ) Popular Amongst Insiders?

Enzo Biochem's Board of Directors Forms New Corporate Development and Planning & Succession Committees

If You Had Bought Enzo Biochem's (NYSE:ENZ) Shares Three Years Ago You Would Be Down 66%

Enzo Biochem Receives FDA Emergency Use Authorization for Testing Pooled Samples on Three Platforms Including company’s GENFLEX™ Proprietary System for Detection of Coronavirus SARS-Cov-2

New 90-day high: US$2.66

Enzo Biochem nabs expanded EUA nod for testing of COVID samples

Enzo Biochem: Betting On The Activists Now

Here's What We Think About Enzo Biochem's (NYSE:ENZ) CEO Pay

First quarter 2021 earnings released: EPS US$0.006

Enzo Biochem, Inc. to Report Q1, 2021 Results on Dec 09, 2020

Enzo Biochem, Inc. Announces Appointment of Ian B. Walters to Board of Directors

Enzo Biochem, Inc. Appoints Mary Tagliaferri to Its Board of Directors